author-photo

Christine Bryla

National Institutes of Health

22

Papers

84

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

The prevalence of altered body image in patients with primary brain tumors: an understudied population

2020 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (3)
QOLP-36. THE IMPORTANCE OF SLEEP DISTURBANCE IN PRIMARY BRAIN TUMOR (PBT) PATIENTS: CLINICAL CHARACTERISTICS & CO-OCCURRENCE WITH TUMOR-RELATED & PSYCHOLOGICAL SYMPTOMS

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
RARE-10. IMPROVING CARE FOR ADULT PATIENTS WITH RARE CNS TUMORS: THE NATIONAL CANCER INSTITUTE-COMPREHENSIVE ONCOLOGY NETWORK EVALUATING RARE CNS TUMORS (NCI-CONNECT) PROGRAM AND CLINIC

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
HOUT-04. ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung

2018 Anti-Cancer Drugs
Show All
- Source
- Cite
- Save
Citations (23)
QLIF-03. UNUSUAL ADVERSE DRUG REACTIONS IN HIGH GRADE GLIOMA PATIENTS TREATED WITH TEMOZOLOMIDE

2017 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
ACTR-69. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR ADULTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA AND GLIOBLASTOMA

2017 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (2)
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

2016 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (24)